Sinotau plans to build a network of five radiopharmaceutical sites across the country within the next three to five years to support in-house R&D activities and commercialization of our radiopharmaceutical portfolio. This network of facilities will integrate manufacturing and labelling of leading nuclear medicine products, training, R&D, and international cooperation activities.
In the near future, Sinotau will be able to rely on its own resources and infrastructure to control the entirely supply chain in China. At the same time, Sinotau will pursue and set collaborations, based on the market needs, with key domestic players and work through their network of sites to reach the whole territory.
It integrates manufacturing and labelling of leading nuclear medicine products, training, R&D and international cooperation activities. Its distribution range covers the Yangtze River Delta. It is an advanced manufacturing site in compliance with U.S.A. and Europe GMP standards.
Its distribution range covers the Pearl River Delta. In this site the company works with 18F, 68Ga, and 99mTc diagnostic drugs.
Its distribution range covers the whole country. Its R&D center and manufacturing capabilities mostly consist of diagnostic agents and therapeutic products.